Phaseline

Companies › Quanta Therapeutics

Quanta Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QTX3544
KRAS G12V inhibitor
KRASPhase 1Advanced Solid TumorsJan 2027
QTX3034
KRAS G12D inhibitor
KRASPhase 1Solid TumorsApr 2027
QTX3046
KRAS G12D inhibitor
KRASPhase 1Advanced Solid TumorJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06715124QTX3544Phase 1Advanced Solid TumorsOncologyJan 2027
NCT06227377QTX3034Phase 1Solid TumorsOncologyApr 2027
NCT06428500QTX3046Phase 1Advanced Solid TumorOncologyJul 2027

Targets

KRAS (3)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics Ranok Therapeutics (Hangzhou)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.